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ImmunohistochemistrySummary Patients with small cell lung carcinoma (SCLC) rarely demonstrate long-term survival. We
previously reported that gene expression profiling identified a subset of SCLC with good prognosis in
surgical cases. To find an easier way to routinely identify SCLC belonging to this subset, we conducted
the present study with a hypothesis that neuroendocrine (NE) or basaloid (BA) phenotypes may
influence prognosis. To confirm the subset, we used an array platform to analyze fresh samples. Because
inoperable cases may differ from surgical cases, we enrolled 51 biopsy cases and 43 resected samples.
To evaluate NE and BA phenotypes, we used NE (synaptophysin, chromogranin A, and CD56) and BA
(p63 and CK34βE12) markers. To varying extents, expression profiling based on the array platform☆☆ Competing interests: The authors have no potential conflicts of interest.
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1046 W. Hamanaka et al.duplicated the subsets. For NE phenotypes, 77% of surgical cases and 100% of biopsy cases were
positive for at least 1 marker. For BA phenotypes, only 19% of surgical cases were positive for at least 1
marker, whereas there were no positive biopsy cases. Cases undergoing surgery were categorized based
on NE and BA immunoreactivity; 58% into NE+BA−, 19% into NE+BA+, 23% into NE−BA−, and 0
into NE−BA+ groups. NE− patients (n = 10) demonstrated a significantly better prognosis (P = .0306)
than their NE+ counterparts (n = 33), whereas no survival difference was evident between the BA+ and
BA− groups. Multivariate analyses showed that NE positivity was an independent prognostic factor. In
conclusion, the SCLC subset with good prognosis is identified by low NE marker expression, which
was found only in surgical cases.
© 2014 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-SA license. 1. Introduction
Small cell lung carcinoma (SCLC) accounts for about
15% of all lung cancers, and its high proliferative activity
generally leads to early metastasis to lymph nodes and dis-
tant organs. It is known that, although more sensitive to
chemotherapy and irradiation than non-SCLCs [1,5], SCLCs
tend to recur in about 70% of cases [6]. Some cases that are
initially misdiagnosed are only found to be SCLC after
resection [7]. Including these cases, it has been found that
stage I SCLC has only a 42% to 66% 5-year survival, which
is much lower than for non-SCLCs [8,9]. These statistics
reflect a disparate course, with some patients with SCLC
surviving for a long time after therapy, whereas others appear
insensitive to chemotherapy and irradiation, implying con-
siderable heterogeneity.
SCLC has distinct histologic characteristics such as scant
cytoplasm (high nucleocytoplasmic [N/C] ratio), ill-defined
cell borders, finely granular nuclear chromatin, absent or
inconspicuous nucleoli, round to spindle shaped, nuclear
molding and rosette formation, extensive necrosis, and a high
mitotic rate [10]. Surgically resected tumors show somewhat
different histology such as larger cell sizes, occasional
conspicuous nucleoli, and vesicular nuclear chromatin [7]. It
is necessary to prove neuroendocrine (NE) differentiation by
immunohistochemistry (IHC) or electron microscopy for the
diagnosis of large cell NE carcinoma (LCNEC). However,
according to the World Health Organization (WHO) classifi-
cation [10], this is not mandatory for SCLC. Nevertheless,
without IHC, it is sometimes difficult to differentiate an SCLC
from a poorly differentiated non-SCLC composed of small-
sized cells with a high N/C ratio, such as basaloid (BA)
carcinoma. In such cases, immunohistochemical markers for
BA cells are useful in distinguishing NE carcinomas from
poorly differentiated squamous cell carcinomas and BA
carcinomas [11,12]. It is important to distinguish such
carcinomas from SCLC because they may have a better
prognosis than SCLC, although BA carcinoma has a poorer
prognosis than usual squamous cell carcinomas.
We previously identified a subset of SCLC with good
prognosis by global gene expression profiling using custom-
made complementary DNA (cDNA) microarrays [13],showing that differentially expressed genes included NE-
related genes, implying that long-term survival is not simply a
matter of chance. To further characterize this subset and define
a more readily accessible technique, such as IHC, to identify
this subset, we set out this study by hypothesizing that a degree
of NE differentiation or a basal cell nature may be related to
prognosis. Because this subset had been delineated in
surgically resected cases and inoperable cases may possibly
differ from surgical cases, we also enrolled inoperable cases
using available biopsy materials. First, we confirmed the
existence of the subset using another platform of gene
expression profiling and then performed IHC with NE and
basal cell markers for surgical and biopsied cases. We paid
particular attention to excluding atypical carcinoids.2. Materials and methods
2.1. Patients and tumor samples
Surgical samples of SCLC are scarce: during the period
from January 1990 to December 2004, a total of 1568 lung
cancers were resected surgically at the Cancer Institute
Hospital, Japanese Foundation for Cancer Research, Tokyo,
Japan. Among these cancers, only 56 cases (3.6%) were found
to be SCLC by pathological examination of resected materials.
In this study, we enrolled a total of 96 SCLC cases, which
were composed of 45 surgical cases and 51 inoperable cases
with only biopsy specimens available. Histologic diagnosis of
SCLC was made according to the 2004 WHO classification
[10], relying only on hematoxylin and eosin (H&E) staining.
Cases with atypical histology were examined by a panel of
Japanese expert pathologists organized by an NE tumor study
group [9], supported by the Ministry of Health, Labour and
Welfare. Also, a few of the atypical cases were presented at
the Pathology Committee meeting of the International
Association for the Study of Lung Cancer, held in Tokyo,
Japan. Atypical carcinoids were carefully excluded, with
special attention to mitosis and cell morphology. Excluding
some SCLC cases with extensive degeneration due to
induction therapy, or with insufficient tumor cells remaining
after chemotherapy, 45 surgical tumors were used for this
Fig. 1 A, Results of unsupervised hierarchical clustering of 30
SCLCs. B, SCLC-specific survival of groups 1 and 2. Note the
better survival of group 2 as compared with group 1 (P = .0014).
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suitable for microarray gene expression analysis (18 were
previously examined [13] and 12 were newly enrolled in this
study), and for the remaining 15 cases, only paraffin blocks
were available. Because for 2 cases among the 30, only fresh
materials were available, no paraffin tissues from surgical
materials being left for this study, tissues of 43 cases were
used for immunohistochemical studies. In addition to the
surgical cases, 51 patients who were inoperable and had
undergone a biopsy between 1996 and 2006 were enrolled.
All tumors were pathologically staged according to the
TNM classification system of the International Union Against
Cancer [14] using resected materials. The clinical stages, serum
level of markers (NSE, ProGRP, CEA, SCC, and CYFRA),
and response rates to chemotherapy were investigated using
medical records. Cumulative smoking was carefully surveyed
and described with reference to the smoking index (SI), defined
as the product of the number of cigarettes per day and duration
in years. Cause of death was surveyed thoroughly using death
certificates, and lung cancer–specific survival or overall
survival was analyzed as appropriate. All tissues were collected
with informed consent from patients, and the study protocol
was approved by the Japanese Foundation for Cancer Research
institutional review board.
2.2. RNA isolation and gene expression profiling
Fresh samples of 30 SCLCs were obtained at surgery. The
tissues of resected tumors were grossly dissected and snap-
frozen in liquid nitrogen typically within 15 minutes of
removal. We always confirmed that fresh tumor tissues for
RNA extraction actually contained viable SCLC cells, using
frozen section diagnosis. Total RNA was extracted using an
RNeasy Mini kit (Qiagen, Hilden, Germany) according to the
manufacturer's instructions. A 3-μg aliquot was used to
generate ds-cDNA using a T7-Oligo (dT) primer, and the
cDNA was transcribed into biotin-labeled cRNA using a
GeneChip 3′ IVT Express Kit (Affymetrix, Santa Clara, CA,
USA). Quality control of RNA and cRNAwas performed using
a bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
After fragmentation, each sample was hybridized to Affymetrix
HG U133 plus 2.0, which covers 38 500 genes, 47 400 tran-
scripts, and more than 54 000 probe sets, and was stained
according to the manufacturer's instructions (Affymetrix). We
used GeneChip Scanner 3000 for scanning and GeneChip
Operating Software (GCOS; Affymetrix) for data output.
2.3. Array data analysis
Data were analyzed and visualized by use of R software
(version 2.9.2; www.t-project.org). Before analysis, all data
were log transformed and subjected to Robust Multichip
Average normalization [15].
Unsupervised hierarchical clustering analysis was accom-
plished with standard Pearson correlations and the Wardmethod using 15 530 probe sets expressed above the back-
ground in at least 20% of the 30 samples and 100 or more
expression signals. To identify genes that represent the most
informativemarkers between 2 groups obtained from clustering
analysis about SCLC, we focused on those with P b .01 by the
Welch t test and log fold-change above 2.0 or below −2.0.
2.4. Procedures for tumor tissue arrays
Surgical specimens were fixed with 15% buffered
formalin and embedded in paraffin. They were sectioned
at 4-μm thickness and stained with H&E for histologic
diagnosis. Tissue arrays were made from paraffin speci-
mens as follows: 2 spots of the most representative tumor
area were selected considering heterogeneity and cored
in 2-mm diameter with a tissue-arraying instrument
(Azumaya, Tokyo, Japan). In cases of combined SCLC,
only SCLC components were chosen for coring. Core
samples were retrieved from donor tissues and arrayed in a
new paraffin block.
Table 1 Patients characteristics of resected SCLC and LCNEC
Cases Ref.
no.
Diagnosis Age Sex SI cT cN cM Preoperative
diagnosis
Induction chemotherapy Operation pT pN
(y) (reduction rate)
1 29635 SCLC 76 M 1500 2 2 0 SCLC Yes PR: 84% Lobectomy 4 2
2 30017 SCLC 57 M 1050 4 2 0 SCLC Yes PR: 70% Lobectomy 4 2
3 30156 SCLC 67 M 940 3 2 0 SCLC or LCC None Lobectomy 4 2
4 30323 SCLC 59 M 1435 2 1 0 SCLC Yes CR: scar+ Lobectomy 2 2
5 30865 SCLC 64 M 400 1 0 0 p/d ca None Lobectomy 1 2
6 31160 SCLC 68 M 1000 1 0 0 SCLC None Lobectomy 4 0
7 31401 SCLC 72 M 680 1 0 0 SCLC None Lobectomy 2 0
8 32658 SCLC 84 M 1200 1 0 0 Unconfirmed None Partial resection 1 1
9 33130 SCLC 46 M 940 1 0 0 SCLC or SQ None Lobectomy 2 0
10 33587 Combined
SCLC + AD
59 M 1480 1 1 0 AD or LCC None Lobectomy 4 0
11 34802 SCLC 73 M 960 1 0 0 SQ None Lobectomy 1 0
12 34947 SCLC 54 M 680 1 0 0 SCLC Yes PR: 74% Lobectomy 1 0
13 35452 Combined
SCLC + AD
F 0 2 0 0 AD None Lobectomy 2 0
14 35628 SCLC 73 M 800 1 2 0 AD or SCLC Yes PR: 77% Lobectomy 1 0
15 35996 SCLC 61 M 375 1 2 0 SCLC Yes PR: 79% Lobectomy 4 2
16 36454 SCLC 66 M 300 1 1 0 SCLC Yes SD: 24% Lobectomy 1 1
17 36483 Combined
SCLC + Spindle
64 M 1470 3 0 0 SCLC Yes PR: 67% Lobectomy 4 0
18 36819 SCLC 67 M 920 2 2 0 SCLC Yes CR: regrowth+ Lobectomy 1 2
19 38779 SCLC 57 M 1110 1 0 0 SCLC Yes SD: 26% Lobectomy 1 1
20 38809 SCLC 79 M 1180 2 0 0 SCLC None Lobectomy 4 0
21 39001 Combined
SCLC + AD
59 M 675 1 0 0 SCLC None Lobectomy 1 0
22 39080 SCLC 76 M 600 1 0 0 AD or SCLC None Segmentectomy 1 0
23 39401 SCLC c 67 M 2000 1 2 0 Unconfirmed None Partial resection 1 0
24 39933 SCLC 53 M 1050 2 1 0 SCLC None Pneumonectomy 4 2
25 40557 Combined
SCLC + AS
74 F 0 2 1 0 NSCLC None Lobectomy 2 2
26 40805 SCLC 68 M 1440 2 0 0 p/d ca None Lobectomy 2 0
27 40914 SCLC 68 F 380 2 0 0 AD or SCLC None Lobectomy 4 1
28 41179 SCLC 65 M 2400 2 1 0 SCLC Yes PR: 51.3% Lobectomy 4 1
29 41310 SCLC 64 F 700 1 0 0 carcinoma None Lobectomy 1 0
30 42085 SCLC 71 M 1060 1 0 0 SCLC or p/d ca None Lobectomy 1 1
31 42253 Combined
SCLC + LCNEC
63 F 1880 3 0 0 SQ or SCLC None Lobectomy 4 0
32 43417 SCLC 74 M 200 2 1 0 NEC None Lobectomy 2 0
33 44106 SCLC 62 M 1175 1 0 0 SCLC Yes PR: 69.5% Lobectomy 1 1
34 44165 Combined
SCLC + LCC
70 M 1000 1 0 0 SCLC or LCC None Lobectomy 2 0
35 44304 Combined
SCLC + LCC
63 M 3760 2 0 0 SCLC None Lobectomy 4 0
36 45819 SCLC 70 F 1000 2 0 0 SCLC Yes SD: 25.2% Lobectomy 2 0
37 46287 SCLC 68 F 160 2 0 0 SCLC Yes PR: 73% Lobectomy 4 0
38 49271 Combined
SCLC + AD
80 M 840 2 0 0 AD None Lobectomy 2 2
39 50455 SCLC 70 M 1000 1 0 0 SCLC None Lobectomy 1 0
40 40245 SCLC 63 M 1660 2 0 0 SCLC Yes PR: 52.6% Lobectomy 2 0
41 42388 Combined
SCLC + AD
74 F 0 1 0 0 AD No Lobectomy 1 1
42 44506 SCLC 56 M 780 1 0 0 SCLC Yes PR: 50% Lobectomy 1 0
43 48003 SCLC 68 F 270 1 0 0 SCLC Yes PR: 47% Lobectomy 1 0
pM p-Stage Size p pm v ly Adj -
CTx
Reccurence Treatment for recurrence Prognosis Final follow-up Cause of death Group
(mm) Regimen Reduction status (d)
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Table 1 (continued )
pM p-Stage Size p pm v ly Adj -
CTx
Reccurence Treatment for recurrence Prognosis Final follow-up Cause of death Group
(mm) Regimen Reduction status (d)
0 IIIB 22 1 1 1 1 Yes Yes CTx PR Dead 296 Pneumonia N+B−
1 IV 50 0 2 1 0 Yes Yes CRTx SD Dead 737 Lung cancer N+B+
0 IIIB 70 3 0 1 1 Yes Yes CTx SD Dead 568 Lung cancer N+B+
0 IIIA 32 0 0 1 1 Yes Yes CRTx CR Dead 616 Lung cancer N+B−
0 IIIA 16 0 0 0 1 Yes None Dead 732 Unknown N+B−
0 IIIB 18 0 1 1 1 Yes None Alive 5825 N−B−
0 IB 33 0 0 1 0 Yes Yes Unknown a Dead 617 Lung cancer N+B+
0 IIA 20 2 0 1 1 None Yes Unknown a Dead 209 Lung cancer N+B−
0 IB 33 0 0 1 0 Yes None Alive 4103 N+B−
0 IIIB 26 0 1 1 1 None None Alive 4029 N+B−
0 IA 24 0 0 1 0 None None Dead 495 Mesentric embolism N+B+
0 IA 22 0 0 1 0 Yes Yes CRTx + Op PD Dead 747 Lung cancer N+B−
0 IB 45 0 0 1 0 Yes None Dead 2691 Unknown N+B−
0 IA 20 1 0 1 0 None None Dead 174 Pneumonia N+B−
0 IIIB 13 0 0 1 1 Yes None Alive 4072 N+B+
0 IIA 16 0 0 1 1 Yes Yes CTx PD Dead 373 Lung cancer N+B−
0 IIIB 42 3 0 1 0 Yes Yes Unknown a Dead 616 Lung cancer N+B−
0 IIIA 25 0 0 1 1 Yes Yes CTx PD Dead 465 Lung cancer N+B+
0 IIA 22 0 0 1 0 Yes Yes RTx PR Dead 948 Lung cancer N+B−
0 IIIB 40 1-3 b 1 1 1 None Yes RTx CR Dead 1098 Lung cancer N+B−
0 IA 20 0 0 1 1 Yes None Alive 2682 N+B−
0 IA 19 0 0 1 0 None Yes CTx SD Dead 1157 Lung cancer N+B−
0 IA 15 0 0 0 0 Yes None Alive 2167 N−B−
0 IIIB 58 3 (interlobe) 0 1 1 None Yes None d Dead 77 Lung cancer N−B−
0 IIIA 54 0 0 1 1 None Yes RTx PD Dead 120 Lung cancer N+B+
0 IB 49 0 0 1 1 Yes None Alive 2623 N−B−
0 IIIB 48 1 1 1 1 Yes Yes RTx CR Dead 815 Lung cancer N+B−
0 IIIB 11 0 1 1 1 None None Dead 312 Lung cancer N+B−
0 IA 30 0 0 0 0 Yes None Dead 702 Respiratory
failure
N−B−
0 IIA 20 0 0 1 1 Yes None Alive 3077 N−B−
0 IIIB 80 3 0 1 0 Yes None Alive 3037 N−B−
0 IB 80 1 0 1 0 Yes None Alive 2772 N−B−
0 IIA 15 2 0 1 1 Yes Yes CRTx PR Dead 1094 Lung cancer N+B−
0 IIB 23 2 0 1 0 None Yes None e Dead 620 Lung cancer N+B−
0 IIIB 21 0 1 1 1 Yes None Alive 2363 N+B+
0 IB 32 1-3 b 0 1 1 Yes None Dead 1203 Unknown N+B−
0 IIIB 53 3 0 1 1 None Yes CRTx PR Dead 538 Lung cancer N+B−
0 IIIA 31 0 0 1 0 Yes Yes Unknown a Dead 760 Lung cancer N+B−
0 IA 22 0 0 1 0 Yes None Alive 1330 N+B−
0 IB 32 1 0 0 1 Yes None Dead 1239 Other cancer N−B−
0 IIA 30 0 0 1 1 No Yes RTx SD Dead 432 Lung cancer N−B−
0 IA 9 0 0 0 0 No Yes RTx PR Dead 792 Lung cancer N+B−
0 IA 11 0 0 0 0 No None Alive 2025 N+B−
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1050 W. Hamanaka et al.2.5. Immunohistochemical analysis
Although histologic diagnosis was made based on H&E
staining, immunohistochemical analyses were performed to
characterize cells. Four-micrometer-thick tissue sections were
mounted on silane-coated slides, routinely deparaffinized in
xylene, and rehydrated through graded ethanol. For antigen
retrieval, the slides were heated at 97°C for 40 minutes in
citrate buffer at pH 6.0 or in EDTA buffer at pH 9.0.
Immunohistochemical staining was performed using the
EnVision+ DAB system with an autostainer (Dako, Glostrup,
Denmark). Endogenous peroxidase activity was blocked with
3% hydrogen peroxide in methanol, and then each antibody
was applied (Supplementary Table 1). We used antibodies for
synaptophysin (SYP), chromogranin A (CGA), and CD56 as
NE markers, as well as antibodies for p63 and high-
molecular-weight cytokeratin (clone 34βE12 or K903) as
basal cell markers (BA). Particular attention was paid to
judgment of immunoreactivity in surgical materials because
we intended to make a comparison between surgical and
biopsy materials. Specifically, to avoid false-negative judg-
ments in surgical materials, we always confirmed that positive
control cells were correctly stained. Immunoreactivity was
scored based on the percentage of cells that stained positively:
negative, 0; less than 10%, 1+; 10% to 50%, 2+; and more than
50%, 3+. Only foci with SCLC morphology were evaluated if
the case was diagnosed as combined with non-SCLC. The
expression of each antibody in a tumor was defined as positive
when 10% of the tumor cells or greater were stained (scores 2+
and 3+) and negative when less than 10% were stained (scores
0 and 1+). We defined cases with either positive p63 or
CK34βE12 as belonging to the BA+ group and cases with any
one of positive SYP, CGA, or CD56 as the NE+ group.
Accordingly, all cases were divided into 4 groups: NE+BA−,
NE+BA+, NE−BA+, and NE−BA−. Two independent ob-
servers (W. H. and Y. I.) pathologically reviewed all slides
without any prior knowledge of patients, and discrepancies
were resolved by joint discussion of the slides viewed with a
multiheaded microscope.
2.6. Analysis of clinicopathological parameters
All analyses were performed using GraphPad PRISM
software (ver 5.0b for Macintosh; GraphPad Software, SanNotes to Table 1
Abbreviations: p, pleural invasion; pm, intrapulmonary metastasis; v, vascular in
partial response; CTx, chemotherapy; CRTx, chemoradiotherapy; RTx, radiothe
complete response; p/d, poorly differentiated; ca, carcinoma; SQ, squamous cell
adenosquamous cell carcinoma; NEC, NE carcinoma.
a Unknown means that the patient had treatment at another hospital.
b Invasion of visceral pleura was graded according to the report of Satoh et
visceral and parietal pleural membranes.
c Double-synchronous primary carcinoma, SQ, and SCLC.
d Patients had best supportive care because of poor performance status.
e Patients had best supportive care because of his own decision.Diego, CA, USA) and SPSS software (ver 15.0; SPSS,
Chicago, IL). We analyzed statistical correlations for
clinicopathological features using the χ2 test with Yate
correction. Survival curves were delineated by Kaplan-
Meier method, and survival difference was tested by the
log-rank test using overall survival or cancer-specific
survival, as appropriate. We also conducted univariate and
multivariate analyses of the prognostic factors using the
Cox proportional hazards model. All differences were
considered statistically significant if P b .05.3. Results
3.1. Gene expression analysis by microarray
To validate the results of the previous study with our
cDNA microarray, 30 SCLCs were enrolled for the current
study. The clinical characteristics of the enrolled cases were
as follows: 21 men and 9 women; average age, 67 years; 27
(90%) were smokers; the median tumor size was 31 mm; and
14 (47%) were at p-stage I.
Unsupervised hierarchical clustering was performed with
15 431 of 54 000 probe sets on oligonucleotide array chips
(Affymetrix HG U133 plus 2.0) expressed stably among all
samples. The result of this clustering is shown in Fig. 1A. We
obtained again 2 clusters, groups 1 and 2, and cases in group
2 had significantly better survival (P = .0014; Fig. 1B). We
compared which genes were differently expressed in these 2
groups (Supplementary Table 2). Cases in group 2 highly
expressed genes related to cell growth (G protein-coupled
receptor, cyclin D1,MYC, etc), but many genes related to NE
differentiation (ASCL1, GRP, NCAM [CD56], CHGA) were
down-regulated.
3.2. Clinical characteristics of SCLC surgical
patients and inoperable patients
As detailed in Table 1, for the surgical patients, the male/
female ratio was 34:9, with a median age of 67 years (range,
46-84 years). Forty patients (95%) were smokers, with an
average SI of 987. The median duration of follow-up was
24 months (range, 1-191 months). Among these, only 23
cases (53%) were definitely diagnosed as having an SCLCvasion; ly, lymphatic involvement; Adj-CTx, adjuvant chemotherapy; PR,
rapy; Op, Operation; LCC, large cell carcinoma; SD, stable disease; CR,
carcinoma; AD, adenocarcinoma; NSCLC, non–small cell carcinoma, AS,
al [16]; p1-3 implies that a tumor extends to connective tissues between
Table 2 Immunoreactivity score and serum markers
Cases Ref.
no.
Immunoreactivity score Serum markers Group
NE SYN CGA NCAM BA p63 K903 Ki-67 (%) CEA SCC CYFRA NSE ProGRP
1 29635 1 3 3 3 0 1 0 90 3.9 1.1 – – – N+B−
2 30017 1 3 3 3 1 3 0 90 6.4 0.5 – – – N+B+
3 30156 1 3 1 1 1 3 1 100 4 1.1 –– – – N+B+
4 30323 1 3 3 3 0 0 0 80 3.1 0.3 – 9.6 – N+B−
5 30865 1 3 3 3 0 0 0 70 2.3 – – – – N+B−
6 31160 0 1 0 1 0 0 1 80 7.1 0.5 – 6.7 – N−B−
7 31401 1 3 0 3 1 1 2 80 4.2 0.7 – 4 – N+B+
8 32658 1 3 3 3 0 1 1 100 3.9 2.1 – – – N+B−
9 33130 1 3 1 3 0 0 0 60 11.2 – – – – N+B−
10 33587 1 3 0 3 0 1 0 70 23.9 – – – – N+B−
11 34802 1 3 1 3 1 3 3 80 4.1 0.9 – – – N+B+
12 34947 1 3 2 3 0 1 0 70 0.8 0.7 – 8.8 – N+B−
13 35452 1 3 3 3 0 0 1 80 5.5 – – 4.6 – N+B−
14 35628 1 3 3 3 0 1 1 100 1.3 4 – 3.2 – N+B−
15 35996 1 3 3 3 1 2 0 80 1.1 – – 1.9 – N+B+
16 36454 1 3 3 3 0 0 0 100 3.2 1.2 – 7.2 – N+B−
17 36483 1 0 1 3 0 1 0 80 3.2 1.4 – 5.1 – N+B−
18 36819 1 3 3 3 1 2 0 80 5.4 0.2 – 14.3 – N+B+
19 38779 1 3 3 3 0 0 1 90 2.1 0.2 – 7.6 70 N+B−
20 38809 1 3 3 3 0 0 0 90 6.7 0.4 – 8.6 – N+B−
21 39001 1 3 3 3 0 0 1 100 2.3 – 1.3 6.4 29.9 N+B−
22 39080 1 3 3 3 0 1 1 70 8.4 – – – – N+B−
23 39401 0 0 1 1 0 0 1 90 3.6 2 – – – N−B−
24 39933 0 0 0 1 0 0 1 70 5.7 0.4 4.5 6.7 17.2 N−B−
25 40557 1 3 3 3 1 3 3 100 2.1 0.4 3.5 7.5 20.5 N+B+
26 40805 0 0 0 1 0 0 0 100 3.5 0.7 1.8 6.5 25.5 N−B−
27 40914 1 3 1 3 0 1 0 100 15.1 0.7 2.4 6.6 72.5 N+B−
28 41179 1 3 3 3 0 1 1 70 3.1 1 – 3.8 151 N+B−
29 41310 0 0 1 1 0 1 0 70 6.3 0.3 1.8 4.9 35.3 N−B−
30 42085 0 1 0 0 0 1 1 80 3 0.6 1.3 2.1 20.8 N−B−
31 42253 0 0 1 0 0 0 0 90 5.2 0.4 4.7 13 26.4 N−B−
32 43417 0 1 0 1 0 0 1 90 1.7 – 2.3 10 26.6 N−B−
33 44106 1 3 3 3 0 1 0 100 2.3 0.7 – – 78.3 N+B−
34 44165 1 3 3 3 0 1 1 90 5.4 1 – – – N+B−
35 44304 1 0 1 2 1 0 3 80 3 0.4 – – 18.6 N+B+
36 45819 1 3 2 1 0 1 1 100 3.9 – – – 49.6 N+B−
37 46287 1 3 3 3 0 0 0 90 5.3 – – 23 638 N+B−
38 49271 1 3 3 3 0 1 1 100 18.8 0.7 – 6.9 56.2 N+B−
39 50455 1 3 3 3 0 0 0 90 2.6 0.6 – – 32.4 N+B−
40 40245 0 0 0 0 0 0 0 80 3 0.2 – 12 24.7 N−B−
41 42388 0 0 0 0 0 0 0 70 4.2 – – – – N−B−
42 44506 1 3 3 3 0 0 0 90 1.9 – 1.2 2.8 16.4 N+B−
43 48003 1 2 3 3 0 0 0 70 0.8 0.9 1.4 – 267 N+B−
Positive ratio
(%)
77 72 58 72 19 14 9 70-100 35 10 27 15 40
N+: positive
ratio (%)
100 94 75 94 24 18 12 86.1 33 9 20 11 62
N−: positive
ratio (%)
0 0 0 0 0 0 0 82 40 12 33 25 0
NOTE. Reference values: CEA, 5.0 ng/mL; SCC, 1.5 ng/mL; CYFRA, 3.5 ng/mL; NSE, 10 ng/mL; ProGRP, 45.9 pg/mL.
1051Small cell lung carcinoma with good prognosisbefore surgery. Most patients received a lobectomy and N2
lymph node dissection, except for 1 segmentectomy for a
stage IA case, 1 pneumonectomy for stage IIB, and 2 partial
resections. These 2 patients underwent partial resectionbecause one was at a high risk (an advanced age and poor
respiratory function) and the other had synchronous double-
lung cancer with lobectomy performed for a larger tumor
diagnosed as squamous cell carcinoma. Postoperatively, 25
1052 W. Hamanaka et al.cases were up-staged after identification of N or T factors.
All information about the surgical patients is shown in
Table 1, including invasion of visceral pleura, as graded for a
previous study [16], and prognosis.
The characteristics of the biopsy group (n = 51) were as
follows: median age, 67 years (range, 54-85 years); male/
female ratio, 44:7; and 96% (43/45) having smoking history
(average SIwas 1152).One-year and 3-year survival rateswere
57% and 2%, respectively. The serum level of ProGRP was
higher than the reference value in 49 (96%) of 51 patients, and
that of NSE was also higher in 27 (82%) of 33 patients.
Histologic review of resected materials confirmed that all
cases were SCLCs according to the WHO classification,
including 9 combined types as follows: 4 cases combined
with adenocarcinomas, 1 with adenosquamous carcinoma, 1
with spindle cell carcinoma, 2 with large cell carcinoma, and
1 with LCNEC. Atypical cases were reviewed and agreed
also by the pathology panel members of the Ministry of
Health, Labour and Welfare study group as well as by some
of the International Association for the Study of Lung Cancer
pathology committee members. Tumors resembling SCLC
such as Ewing sarcoma, poorly differentiated synovial
sarcoma, lymphoma, squamous cell carcinoma composed
of small-sized cells, and BA carcinoma were excluded, based
on IHC results and/or close histopathologic observation.ig. 2 Representative histologic pictures of SCLC subsets by NE
ifferentiation and BA phenotypes (H&E, original magnification
40). A, NE+BA−. B, NE+BA+. C, NE−BA−. Notably, there are
lmost no histopathologic differences among the 3 tumors, in-
luding mitosis counts.3.3. NE and BA phenotypes in surgical and
biopsied cases
Of the surgical patients, 31 (72%) were positive for SYN,
25 (58%) for CGA, 31 (72%) for CD56, 6 (14%) for p63, and
4 (9%) for CK34βE12. Percentages of NE marker positivity
(58%-72%) were similar to the previous study based on
surgery (57%-58% for SYN and CGA [7]). Immunoreactiv-
ity of BA markers might be explained by combined
components with SCLC [12], although some cells were
positive for both NE and BA markers. Interestingly, there
were 8 patients (19%) positive for at least 1 BA marker, and
10 (23%) were negative for all NE markers (Table 2).
According to these results, all cases could be classified into 4
subgroups: NE+BA− (n = 25; 58%), NE+BA+ (n = 8; 19%),
NE−BA+ (n = 0), and NE−BA− (n = 10; 23%). His-
tologically, or using the Ki-67 index, it was difficult to
distinguish among the 3 groups (Fig. 2; Table 2). When we
compared immunoreactivity with several serum markers, the
ProGRP value was significantly higher in the NE+ group,
and no patients had an abnormal value in the NE− group (P =
.023; Table 2), implying a good correlation of the NE
phenotype between serum and tumors.
We examined concordance of classification by gene
expression profiling and IHC phenotyping. Of 30 SCLC
cases analyzed by gene expression profiling, 28 were suc-
cessfully examined by IHC. All 12 cases classified to group 1
(poor prognosis group) by gene expression profiling fell into





Table 3 Comparison of clinicopathological features in the SCLC subgroups with/without NE and BA natures
Variable No. of
cases (n = 43)
NE markers P BA markers P
Negative (n = 10) Positive (n = 33) Negative (n = 35) Positive (n = 8)
Age (y) .481 .7381
b60 10 1 9 9 1
N61 33 9 24 26 7
Sex .718 .8666
Male 34 7 27 27 7
Female 9 3 6 8 1
Smoking status .779 .9287
Never 3 1 2 2 1
Smoker 40 9 31 33 7
Tumor size (mm) .818 .9044
≦30 25 5 20 21 4
N30 18 5 13 14 4
Lymph node metastasis .616 .3605
Negative 25 7 18 22 3
Positive 18 3 15 13 5
Pathological stage .687 .5953
I 17 5 12 15 2
II-IV 26 5 21 20 6
Combined subtypes 10 2 8 8 2
AD 5 1 4 5 0
SQ 0 0 0 0 0
AS 1 0 1 0 1
Spindle 1 0 1 1 0
LCC 2 0 2 1 1
LCNEC 1 1 0 1 0
Induction CTx .049 .9044
Negative 25 9 16 20 5
Positive 18 1 17 15 3
Adjuvant CTx .56 .9303
Negative 14 2 12 12 2
Positive 29 8 21 23 6
Abbreviations: AD, adenocarcinoma; SQ, squamous cell carcinoma; AS, adenosquamous cell carcinoma; LCC, large cell carcinoma; CTx, chemotherapy.
NOTE. All were analyzed by χ2 test with Yate correction.
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other 7 in the NE+ group. The concordance rates for groups 1
and 2 were 100% (12/12) and 56% (9/16), respectively.
For biopsy cases, all but 1 were positive for all the 3
NE markers and all were negative for the 2 BA markers.
Only 1 patient was negative for CD56 and positive for SYN
and CGA. As compared with surgical cases, therefore, the
tumors of biopsy cases had a marked NE nature and lacked
BA phenotypes.
3.4. Clinicopathological comparison between NE or
BA expression and prognosis
We evaluated clinicopathological characteristics accord-
ing to immunoreactivity for NE and BA markers (Table 3).
Unfortunately, only 1 patient in the NE− group underwent
induction chemotherapy, so we could not evaluate if the NE−
tumors were chemosensitive or not. Rather, this indicated
that tumors of the NE− group had almost no influence of
chemotherapy and that their characteristics identified by IHCwere innate, implying that the results of low NE expression
were reliable. No factors showed any significant difference
between the BA+ and BA− groups.
SCLC-specific survival curves of NE+/− and BA+/−
groups are shown in Fig. 3. There was no difference based on
the presence of BA phenotypes (P = .28; Fig. 3A), but NE
phenotypes were critical for patient survival. In fact, the NE−
group had a significantly better prognosis than did the NE+
group (P = .03; Fig. 3B). Among the 3 groups (NE+BA+, NE
+BA−, NE−BA−), the NE−BA− group also showed a sig-
nificant tendency toward a better outcome (P = .036; Fig. 3C).
3.5. Univariate and multivariate analyses of factors
influencing prognosis
Thirty-three surgically treated patients underwent both
lobectomy (single or bilobectomy) and platinum-based double
chemotherapy (induction and/or adjuvant, ≥4 courses). We
used this group with the same treatment condition to evaluate
the factors influencing prognosis. Univariate analyses for
Fig. 3 SCLC-specific survival for patients with or without BA
markers (A), P = .278, and NE markers (B), P = .0306. C, the NE−
BA− group features a significantly better prognosis than the others.
1054 W. Hamanaka et al.overall survival showed that patients negative for NE markers
tended to have good prognosis (P = .047; Table 4A). When
using SCLC-specific survival, univariate analysis showed that
both pathological stages (P = .016) and NE marker reactivity
(P = .012) were significant markers for good prognosis. Age,
SI, lymphovascular invasion, and BA marker immunoreactiv-
ity had no prognostic value. Multivariate analyses revealed
that NE marker expression was the only independent factor
influencing prognosis (Table 4B; risk ratio, 5.577; 95%confidence interval [CI], 1.172-26.524; P = .031).Multivariate
analysis for SCLC-specific survival did not produce any
significant results probably because the NE− group included
no SCLC-specific deaths.3.6. Induction chemotherapy and its effects
on survival
Of the 43 surgical patients analyzed here, 17 (40%)
underwent induction chemotherapy, and the reduction rate
ranged from 24% to complete response, as detailed in Table 1.
Because pretreatment might have some effect on prognosis,
we performed survival analyses using 26 cases without
pretreatment by comparing SCLC-specific survival between
N+ (n = 17) and N− (n = 9) subgroups. As shown in
Supplementary Fig. 1A, the survival of NE− subgroup was 3
times better than the NE+ subgroup. Although the difference
was not significant (P = .148), this was probably due to the
small number of cases. Furthermore, we compared SCLC
death rates and survival difference of NE+ cases (n = 33)
between those with induction chemotherapy (n = 16) and
without (n = 17). They were 11 (69%) of 16 for cases with the
pretreatment and 9 (53%) of 17 for cases without andwere not
significantly different. Also, as Supplementary Fig. 1B
indicates, survival was not different between the 2 subgroups
(P = .19), although the number of cases was larger than the
analysis using non-pretreated cases. Based on these findings,
we used all the cases including cases both with and without
pretreatments for survival analysis.4. Discussion
To our knowledge, this is the first report describing a
hitherto unmarked SCLC subtype with a good prognosis,
using substantial numbers of surgically resected cases. Here
we demonstrated that the subtype can be detected by IHC
alone using NE markers such as SYP, CGA and CD56.
Previously, we identified the subtype by global gene ex-
pression profiling using cDNA microarrays. The current
study, using oligonucleotide arrays (by Affymetrix), dupli-
cated fairly well the subset with additional new cases. Also
in this study, we focused on characterizing the SCLC sub-
set by hypothesizing that low expression of NE-related
proteins and/or a BA nature of tumor cells might explain
differences from standard SCLCs.
In fact, BA carcinoma histologically resembles SCLC,
and the BA pattern is a marker for worse prognosis for non-
SCLC [17]. Our univariate and multivariate analyses reveal,
however, that expression of NE markers is a prognostic
factor, but the BA phenotype in terms of CK34βE12 and
p63 protein expression has no effect on survival. The im-
munohistochemically defined obvious subtype of SCLC
with a good prognosis comprised 23% of the surgically
resected SCLC. Because there were no such cases in
Table 4 Univariate and multivariate analyses on factors influencing overall survival, based on all cases (n=96, surgery [n=45] and biopsy
[n=51]). (A) analyses for SCLC-specific survival (B)
Parameters A B
Univariate Multivariate Univariate
P P Exp (coefficient) Lower (95% CI) Upper (95% CI) P
Age (N60 y) .900 .666 1.256 0.447 3.525 .618
Sex .777 .303
Pathological stage (NI) .135 .095 2.381 0.860 6.592 .016
Vascular invasion .886 .174
Lymphatic invasion .827 .534
NE marker .047 .031 5.577 1.172 26.524 .012
BA marker .777 .331 0.559 0.173 1.804 .208
1055Small cell lung carcinoma with good prognosisinoperable patients, we could not perform a study using
only biopsy materials.
According to the current WHO criteria for NE tumors, it is
necessary to prove NE phenotypes for LCNEC diagnosis, but
not for SCLCs. In the present study, approximately 80% of
surgical tumors had NE phenotypes, largely consistent with
the previous studies [7,18,20], and all the biopsy cases had
obvious NE phenotypes proven by IHC. Although this fact
suggests that the current WHO criteria work quite well, they
are insufficient to distinguish the atypical SCLC subtype with
a good prognosis, particularly for surgical cases.
Serum tumor markers including NSE, ProGRP, and CD56
are useful for clinical diagnosis of SCLC, and their im-
munohistochemical staining has been used for discrimina-
tion of NE tumors from others. However, their prognostic
value has proved controversial [21,23]. In this study, we
demonstrated immunohistochemical use for outcome predic-
tion. Also, the NE marker levels in serum tended to be higher
in the groupwith a poor prognosis. In fact, almost all the cases
with elevated serum markers belonged to the poor prognosis
group, as shown in Table 2. Because the number of cases with
measured serum NE markers in the good prognosis group is
limited, we should continue comparing the prognosis
between groups with and without elevated values.
Chemosensitivity and radiosensitivity is crucial for SCLC
treatment. Unfortunately, we were unable to determine if our
NE− (negative) group was chemosensitive or not because
none of the cases underwent induction chemotherapy or
treatment of a recurrent tumor. We should further investi-
gate sensitivity by accumulating more cases of this particular
SCLC subtype.
Although it is difficult to distinguish histologically an
SCLC subtype with a good prognosis, such a subtype may
exist, which has distinct cellular and genetic characteristics.
In our previous study [13], we performed an integrated
analysis using clinical SCLC tumors and established SCLC
cell lines. As a matter of fact, there were no cell lines that
clustered together with the good prognosis subtype. There-
fore, further studies may include establishing cell lines of this
particular SCLC subtype.Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.humpath.2014.01.001.Acknowledgments
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